Literature DB >> 24530213

Thromboprophylaxis use and concordance with guidelines among medical and surgical patients in Morocco.

Tazi Mezalek Zoubida1, Abderahim Azzouzi2, Wafaa Bono3, Rajae Tachinante4, Mamoun Faroudy5, Lamiaa Essaadouni6, Chakib Nejjari7.   

Abstract

INTRODUCTION: No data are available on thromboprophylaxis use in Morocco. Our aim was to characterize patients at risk of venous thromboembolism and assess the rate of appropriate thromboprophylaxis.
MATERIALS AND METHODS: This was a national, observational, multicentre survey of venous thromboembolism risk and thromboprophylaxis use in hospitalized patients. Data were collected on a predefined date in three university hospitals in Morocco using a standardized pre-printed form. Thromboembolic risk was assessed according to the American College of Chest Physicians (ACCP) 2008 guidelines. Patients were classified as "thromboprophylaxis indicated" or "thromboprophylaxis not indicated".
RESULTS: 784 patients were analysed: 307 (39.2%) medical and 477 (60.8%) surgical. 421 (53.7%) were female. Medical patients were older than surgical patients (57.6 ± 11.5 vs. 46.2 ± 16.9 years, p<0.0001) and were more likely to have risk factors for thromboembolism (50.5% vs. 45.7% of patients, p=NS). 57% of patients without contraindications or bleeding risk were at risk of thromboembolism according to ACCP guidelines and thromboprophylaxis was prescribed to 42.8% of these patients. In contrast, 7.4% of patients with no thromboembolic risk also received thromboprophylaxis (proportion agreement: 61.0%; Kappa=0.296). Over half (54.5%) of medical patients at risk of thromboembolism did not receive thromboprophylaxis whereas 6.3% of those with no risk did receive it (proportion agreement: 76.4%; Kappa=0.433). These figures were 57.9% and 9.2%, respectively, for surgical patients (proportion agreement: 52.7%; Kappa=0.191). Thromboprophylaxis was given to 19.2% of patients with contraindications or a bleeding risk.
CONCLUSIONS: Educational initiatives are imperative to inform doctors about appropriate thromboprophylaxis.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Contraindications; Hospitalized patients; Observational study; Risk factors; Thromboprophylaxis; Venous thromboembolism

Mesh:

Substances:

Year:  2014        PMID: 24530213     DOI: 10.1016/j.thromres.2014.01.036

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  1 in total

1.  Evaluation and management of thromboprophylaxis in Moroccan hospitals at national level: the Avail-MoNa study.

Authors:  Z Tazi Mezalek; C Nejjari; L Essadouni; M Samkaoui; K Serraj; W Ammouri; N Kanjaa; Z Belkhadir; B Housni; M Awab; M Faroudy; W Bono; S Kabbaj; M Akkaoui; M Barakat; R Rifai; H Charaf; A Aziz; Y Elachhab; A Azzouzi
Journal:  J Thromb Thrombolysis       Date:  2018-07       Impact factor: 2.300

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.